Cynthia Huang Bartlett
AstraZeneca (Netherlands)(NL)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer-related Molecular Pathways, Lung Cancer Research Studies, Cancer Treatment and Pharmacology
Most-Cited Works
- → Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial(2016)1,795 cited
- → Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer(2015)1,569 cited
- → Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer(2018)1,261 cited
- → Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer(2016)702 cited
- → The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial(2018)656 cited
- → Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer(2019)445 cited
- → Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up(2019)426 cited
- → Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer(2018)409 cited
- → NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer(2017)371 cited
- → Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study(2021)250 cited